Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $76

Gilead Sciences, Inc. -1.29%

Gilead Sciences, Inc.

GILD

72.56

-1.29%

Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ: GILD) with a Equal-Weight and lowers the price target from $80 to $76.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via